NASDAQ:OBIO Orchestra BioMed (OBIO) Stock Price, News & Analysis → Breaking - The US Gov. Seized CITGO (From Augury Research) (Ad) Free OBIO Stock Alerts $7.98 -0.01 (-0.13%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$7.81▼$8.1050-Day Range$4.39▼$7.9952-Week Range$4.22▼$14.87Volume54,237 shsAverage Volume83,640 shsMarket Capitalization$285.60 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Orchestra BioMed alerts: Email Address Orchestra BioMed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside113.0% Upside$17.00 Price TargetShort InterestBearish4.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.34Based on 3 Articles This WeekInsider TradingAcquiring Shares$28,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.58) to ($1.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.84 out of 5 starsMedical Sector581st out of 904 stocksSurgical & Medical Instruments Industry69th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingOrchestra BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOrchestra BioMed has only been the subject of 1 research reports in the past 90 days.Read more about Orchestra BioMed's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.05% of the float of Orchestra BioMed has been sold short.Short Interest Ratio / Days to CoverOrchestra BioMed has a short interest ratio ("days to cover") of 21, which indicates bearish sentiment.Change versus previous monthShort interest in Orchestra BioMed has recently decreased by 2.65%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOrchestra BioMed does not currently pay a dividend.Dividend GrowthOrchestra BioMed does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OBIO. Previous Next 3.0 News and Social Media Coverage News SentimentOrchestra BioMed has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Orchestra BioMed this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for OBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchestra BioMed insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of Orchestra BioMed is held by insiders.Percentage Held by Institutions53.55% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Orchestra BioMed's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Orchestra BioMed are expected to decrease in the coming year, from ($1.58) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchestra BioMed is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchestra BioMed is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchestra BioMed has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Orchestra BioMed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", About Orchestra BioMed Stock (NASDAQ:OBIO)Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Read More OBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OBIO Stock News HeadlinesJune 4, 2024 | insidertrades.comInsider Buying: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Purchases 4,000 Shares of StockJune 4, 2024 | americanbankingnews.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider William Reed Little Acquires 4,000 SharesMay 22, 2024 | globenewswire.comOrchestra BioMed to Participate in Jefferies Global Healthcare ConferenceMay 15, 2024 | msn.comOrchestra BioMed Unveils Q1 2024 Financial Results, Advances Pivotal Studies on Innovative Medical TherapiesMay 14, 2024 | finanznachrichten.deOrchestra BioMed Holdings, Inc.: Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 14, 2024 | markets.businessinsider.comBuy Rating Endorsed for OBIO on Strong Financials and Promising BackBeat CNT ProspectsMay 13, 2024 | investorplace.comOBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024May 13, 2024 | globenewswire.comOrchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 1, 2024 | msn.comOrchestra BioMed Expands Global Patent Portfolio for Hypertension TherapyApril 30, 2024 | globenewswire.comOrchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued PatentsMarch 31, 2024 | msn.comOrchestra BioMed: Continuing the Momentum into a Promising FutureMarch 31, 2024 | msn.comOrchestra BioMed Bolsters Board with Healthcare Industry Veteran David PacittiMarch 29, 2024 | finance.yahoo.comOrchestra BioMed Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Clinical DataMarch 27, 2024 | investorplace.comOBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023March 27, 2024 | globenewswire.comOrchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateMarch 26, 2024 | globenewswire.comOrchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of DirectorsMarch 11, 2024 | msn.comOrchestra BioMed's AVIM Therapy Demonstrates Promising Results in Controlling HypertensionMarch 7, 2024 | globenewswire.comOrchestra BioMed to Participate in Upcoming Investor ConferencesMarch 6, 2024 | globenewswire.comOrchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker PatientsFebruary 16, 2024 | finance.yahoo.comWhy Orchestra BioMed (OBIO) Might Surprise This Earnings SeasonJanuary 19, 2024 | benzinga.comOrchestra BioMed Hldgs Stock (NASDAQ:OBIO), Short Interest ReportJanuary 19, 2024 | msn.comJefferies starts Orchestra BioMed at buy, cites lead program opportunitiesJanuary 16, 2024 | morningstar.comOrchestra BioMed Holdings Inc OBIOJanuary 8, 2024 | sg.finance.yahoo.comSilicon Box Accelerates Industry Leadership With Production Commencement at its World Leading Advanced Packaging Facility and Series B FundraisingSee More Headlines Receive OBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/08/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:OBIO CUSIPN/A CIK1814114 Weborchestrabiomed.com Phone646-597-6980FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Target$17.00 High Stock Price Target$20.00 Low Stock Price Target$14.00 Potential Upside/Downside+113.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,120,000.00 Net Margins-2,330.46% Pretax Margin-2,330.46% Return on Equity-70.18% Return on Assets-49.17% Debt Debt-to-Equity RatioN/A Current Ratio7.34 Quick Ratio7.33 Sales & Book Value Annual Sales$2.76 million Price / Sales103.48 Cash FlowN/A Price / Cash FlowN/A Book Value$1.90 per share Price / Book4.20Miscellaneous Outstanding Shares35,790,000Free Float33,390,000Market Cap$285.60 million OptionableNot Optionable Beta0.42 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. David P. Hochman (Age 49)Founder, Chairman of the Board of Directors & CEO Comp: $942kMr. Darren R. Sherman (Age 53)Founder, President, COO & Director Comp: $787kMr. Andrew Lawrence Taylor M.B.A. (Age 53)Chief Financial Officer Comp: $326.37kMr. William Reed Little (Age 52)Executive VP of Corporate Development & Strategy Dr. Yuval Hay Mika D.Sc (Age 65)Ph.D., GM & CTO of Bioelectronic Therapies Dr. George Papandreou Ph.D. (Age 59)GM & Senior VP of Focal Therapies Dr. Hans-Peter Stoll M.D.Ph.D., Chief Clinical OfficerDr. Avraham Matityahu Fischer M.D. (Age 68)Senior Vice President of Medical Affairs & Innovation Mr. Bob LaughnerSenior Vice President of Regulatory & QualityMr. Juan LorenzoSenior Vice President of Product DevelopmentMore ExecutivesKey CompetitorsArtivionNYSE:AORTPerspective TherapeuticsNYSE:CATXSilk Road MedicalNASDAQ:SILKAtrionNASDAQ:ATRIPulse BiosciencesNASDAQ:PLSEView All CompetitorsInsiders & InstitutionsWilliam Reed LittleBought 4,000 shares on 5/30/2024Total: $28,000.00 ($7.00/share)Price T Rowe Associates Inc. MDSold 51,533 shares on 5/15/2024Ownership: 1.596%Catalytic Wealth RIA LLCBought 22,261 shares on 5/11/2024Ownership: 0.062%View All Insider TransactionsView All Institutional Transactions OBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Orchestra BioMed stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Orchestra BioMed in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OBIO shares. View OBIO analyst ratings or view top-rated stocks. What is Orchestra BioMed's stock price target for 2024? 2 equities research analysts have issued 1-year price objectives for Orchestra BioMed's stock. Their OBIO share price targets range from $14.00 to $20.00. On average, they expect the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 113.0% from the stock's current price. View analysts price targets for OBIO or view top-rated stocks among Wall Street analysts. How have OBIO shares performed in 2024? Orchestra BioMed's stock was trading at $9.13 at the beginning of the year. Since then, OBIO shares have decreased by 12.6% and is now trading at $7.98. View the best growth stocks for 2024 here. When is Orchestra BioMed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our OBIO earnings forecast. How were Orchestra BioMed's earnings last quarter? Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) released its earnings results on Monday, May, 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. The business had revenue of $0.62 million for the quarter, compared to analyst estimates of $1.28 million. Orchestra BioMed had a negative trailing twelve-month return on equity of 70.18% and a negative net margin of 2,330.46%. Who are Orchestra BioMed's major shareholders? Orchestra BioMed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (1.60%) and Catalytic Wealth RIA LLC (0.06%). View institutional ownership trends. How do I buy shares of Orchestra BioMed? Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OBIO) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersSecret energy grid to power millions of homesThis high-security, secret U.S. facility has 2,100 engineers, machinists, and technicians building a new type ...Porter & Company | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchestra BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.